Integrative genetic characterization and phenotype correlations in pheochromocytoma and paraganglioma tumours.

Crona J, Nordling M, Maharjan R, Granberg D, Stålberg P, Hellman P, Björklund P

PLoS ONE 9 (1) e86756 [2014-01-22; online 2014-01-22]

About 60% of Pheochromocytoma (PCC) and Paraganglioma (PGL) patients have either germline or somatic mutations in one of the 12 proposed disease causing genes; SDHA, SDHB, SDHC, SDHD, SDHAF2, VHL, EPAS1, RET, NF1, TMEM127, MAX and H-RAS. Selective screening for germline mutations is routinely performed in clinical management of these diseases. Testing for somatic alterations is not performed on a regular basis because of limitations in interpreting the results. The purpose of the study was to investigate genetic events and phenotype correlations in a large cohort of PCC and PGL tumours. A total of 101 tumours from 89 patients with PCC and PGL were re-sequenced for a panel of 10 disease causing genes using automated Sanger sequencing. Selected samples were analysed with Multiplex Ligation-dependent Probe Amplification and/or SNParray. Pathogenic genetic variants were found in tumours from 33 individual patients (37%), 14 (16%) were discovered in constitutional DNA and 16 (18%) were confirmed as somatic. Loss of heterozygosity (LOH) was observed in 1/1 SDHB, 11/11 VHL and 3/3 NF1-associated tumours. In patients with somatic mutations there were no recurrences in contrast to carriers of germline mutations (P = 0.022). SDHx/VHL/EPAS1 associated cases had higher norepinephrine output (P = 0.03) and lower epinephrine output (P<0.001) compared to RET/NF1/H-RAS cases. Somatic mutations are frequent events in PCC and PGL tumours. Tumour genotype may be further investigated as prognostic factors in these diseases. Growing evidence suggest that analysis of tumour DNA could have an impact on the management of these patients.

NGI Uppsala (SNP&SEQ Technology Platform)

QC bibliography QC xrefs

PubMed 24466223

DOI 10.1371/journal.pone.0086756

Crossref 10.1371/journal.pone.0086756


pmc PMC3899286